Inactive Instrument

Checkmate Pharmaceuticals, Inc.

CMPI

US1628181083

Biotechnology & Medical Research

Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index

May 31, 2022 at 09:30 am IST

Latest news about Checkmate Pharmaceuticals, Inc.

Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	02/22/02	MT
Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	02/22/02	MT
Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer	31/22/31	CI
Checkmate Pharmaceuticals, Inc. Announces Board Changes	31/22/31	CI
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index	31/22/31	CI
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index	31/22/31	CI
Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	27/22/27	CI
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	27/22/27	CI
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Kuros Biosciences' Q1 Medical Devices Sales Surge 102% Following US FDA Approval For MagnetOs	27/22/27	MT
BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	20/22/20	MT
Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets	20/22/20	MT
Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets	19/22/19	MT
Top Midday Gainers	19/22/19	MT
Sector Update: Health Care	19/22/19	MT
Checkmate Pharmaceuticals Shares Take Flight on Regeneron Deal	19/22/19	DJ
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	19/22/19	MT
Wall Street in Holding Pattern Pre-Bell as 10-Year Yield Tops 2.9%	19/22/19	MT
Sector Update: Health Care	19/22/19	MT
Top Premarket Gainers	19/22/19	MT
Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million	19/22/19	DJ
Regeneron Pharmaceuticals Agrees to Buy Checkmate Pharmaceuticals in $250 Million All-Cash Deal	19/22/19	MT
Regeneron Pharmaceuticals, Inc. entered into a definitive agreement to acquire Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others for approximately $250 million.	19/22/19	CI
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research Annual Meeting	08/22/08	CI
BTIG Adjusts Checkmate Pharmaceuticals' Price Target to $9 from $29, Keeps Buy Rating	30/22/30	MT

Chart Checkmate Pharmaceuticals, Inc.

Duration

Period

More charts

Checkmate Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. The Company's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The Company is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The Company is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The Company's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.22B
ARGENX SE	+0.44%	22.27B
GENMAB A/S	-4.18%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B
LEGEND BIOTECH CORPORATION	-23.95%	8.34B

Bio Therapeutic Drugs